Research Analysts Set Expectations for Harrow Q1 Earnings

Harrow, Inc. (NASDAQ:HROW) – Research analysts at William Blair lifted their Q1 2026 earnings estimates for shares of Harrow in a note issued to investors on Monday, September 29th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.23) per share for the quarter, up from their prior estimate of ($0.27). William Blair has a “Outperform” rating on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share.

Other research analysts have also recently issued research reports about the stock. B. Riley reiterated a “buy” rating and issued a $74.00 price target (up previously from $70.00) on shares of Harrow in a report on Wednesday. Zacks Research cut Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. Lake Street Capital lifted their price objective on shares of Harrow from $42.00 to $70.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $64.00 target price on shares of Harrow in a research report on Monday. Finally, Cantor Fitzgerald began coverage on Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.50.

Harrow Trading Down 1.3%

Shares of NASDAQ HROW opened at $47.73 on Wednesday. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -190.92 and a beta of 0.27. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The company’s fifty day moving average is $39.38 and its 200-day moving average is $32.07.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS.

Institutional Trading of Harrow

Institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Harrow by 89.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock valued at $2,078,000 after buying an additional 29,262 shares during the period. GAMMA Investing LLC increased its position in Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company’s stock worth $1,670,000 after purchasing an additional 6,027 shares in the last quarter. Rhumbline Advisers lifted its stake in Harrow by 7.2% in the 1st quarter. Rhumbline Advisers now owns 42,975 shares of the company’s stock valued at $1,143,000 after purchasing an additional 2,879 shares during the last quarter. Woodmont Investment Counsel LLC boosted its position in Harrow by 27.4% in the first quarter. Woodmont Investment Counsel LLC now owns 103,693 shares of the company’s stock valued at $2,758,000 after buying an additional 22,293 shares in the last quarter. Finally, Westside Investment Management Inc. grew its stake in shares of Harrow by 6.3% during the first quarter. Westside Investment Management Inc. now owns 173,856 shares of the company’s stock worth $4,625,000 after buying an additional 10,315 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.